Yes, Trulicity Is a Once-Weekly Injection
Trulicity (dulaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes management. Patients inject it subcutaneously once every week, on the same day each week, with or without food. The pre-filled pen delivers doses of 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg, and it can be used alongside diet and exercise or other diabetes medications.[1][2]
How Do You Administer Trulicity?
Inject in the abdomen, thigh, or upper arm. Rotate sites weekly to avoid irritation. No priming or mixing required—the single-use pen is ready after removing the cap. Store in the fridge but allow to reach room temperature before use. If a dose is missed, take it within 3 days; otherwise, skip and resume the regular schedule.[1][3]
What Happens If You Miss a Dose?
Missing by more than 3 days means skipping it entirely to avoid doubling up, which could raise side effect risks like nausea. Consistent weekly timing helps maintain steady blood sugar control.[2]
Common Side Effects Patients Report
Nausea (most frequent, often improves over time), vomiting, diarrhea, abdominal pain, and injection-site reactions like redness. Hypoglycemia risk increases when combined with insulin or sulfonylureas. Serious but rare issues include pancreatitis, gallbladder problems, or thyroid tumors (boxed warning).[1][3]
How Does Trulicity Compare to Other GLP-1 Drugs?
| Drug | Dosing Frequency | Key Differences |
|------|------------------|-----------------|
| Trulicity (dulaglutide) | Once weekly | Higher doses available; no titration needed for some. |
| Ozempic (semaglutide) | Once weekly | Similar efficacy; also used for weight loss (Wegovy version). |
| Victoza (liraglutide) | Daily | More frequent injections; slightly different side effect profile. |
| Mounjaro (tirzepatide)* | Once weekly | Dual GLP-1/GIP action; often stronger A1C and weight loss results. |
*Mounjaro is a competitor with pending patent challenges.[4]
When Does Trulicity's Patent Expire?
Key U.S. patents on dulaglutide expire around 2029-2033, with some formulation patents extending to 2034. Eli Lilly faces biosimilar challenges; no approved generics yet.[5]
[1]: Trulicity Prescribing Information (FDA)
[2]: Eli Lilly Trulicity Site
[3]: Drugs.com Trulicity Page
[4]: GoodRx GLP-1 Comparison
[5]: DrugPatentWatch.com - Trulicity Patents